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The effect of morphine on breathing and ventilatory chemoreflexes in obstructive sleep apnea (OSA) is 
unknown. It has been assumed that acute morphine use may induce deeper respiratory depression in OSA but 
this has not been investigated. We evaluated awake ventilatory chemoreflexes and overnight 
polysomnography on 10 mild-moderate OSA patients before and after giving 30mg oral controlled-release 
morphine. Morphine plasma concentrations were analysed.  We found a 30-fold range of morphine plasma 
concentrations with the fixed dose of morphine, and a higher plasma morphine concentration was associated 
with a higher CO2 recruitment threshold (VRT) (r=0.86, p=0.006) and an improvement in sleep time with 
2O
Sp
<90% (T90) (r=-0.87, p=0.005) compared to the baseline. The improvement in T90 also significantly correlated 
with the increase of VRT (r=-0.79, r=0.02).  In conclusion, in mild-to-moderate OSA patients, a single common 
dose of oral morphine may paradoxically improve OSA through modulating chemoreflexes. There is a large 
inter-individual variability in the responses which may relate to individual morphine metabolism. 
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1. INTRODUCTION  
Opioids are commonly used in a number of clinical settings, including treatment of pain, trauma, cancer and in 
opioid maintenance treatment programs. The number of opioid prescriptions has increased dramatically in the 
past decade.  In the USA, the therapeutic use of methadone and oxycodone increased by 824% and 660%, 
respectively, between 1997 and 2003 (US Department of justice and Drug Enforcement Administration, 2005). 
In Australia, the number of Pharmaceutical Benefits Scheme (PBS) opioid prescriptions increased three-fold, 
from 2.4-million in 1992 to 7.0-million in 2007 (Leong et al., 2009). Meanwhile, mortality rates from 
unintentional drug overdose have also increased substantially, with deaths attributed primarily to prescription 
opioid analgesics (more than 90%) (Centres for Disease Control and Prevention, 2007; Hall et al., 2008; Okie, 
2010). In Australia, there was a three-fold increase in the number of hospitalisations as a result of 
unintentional overdose by opioids other than heroin and methadone from 1998/99 to 2006/07 (National 
hospital morbidity database, 2008). Death from opioids is nearly always due to respiratory arrest (Caplehorn 
and Drummer, 1999; Gutstein and Akil, 2005). Acute opioid use can reduce vital ventilatory chemoreflexes and 
cause severe hypoventilation (Bailey et al., 2000), with the immediate cause of death often being pulmonary 
oedema secondary to prolonged hypoventilation (Caplehorn and Drummer, 1999). 
 
During sleep, respiration is naturally depressed and mainly under automatic neural-chemical control (Douglas, 
2000). Acute opioid use significantly reduces protective chemoreflexes, and patients have an increased risk of 
respiratory arrest during sleep (Dempsey et al., 2010). As a common disease, obstructive sleep apnea (OSA) 
is characterized by repetitive pauses in breathing during sleep due to the collapse and/or narrowing of the 
upper airway, and is usually associated with a reduction in blood oxygen saturation. The effect of opioids on 
OSA is unknown. No carefully designed clinical trial has investigated the effect of opioids in OSA (Chung et al., 
2008; Macintyre et al., 2011). Current knowledge is based on observational case studies and retrospective 
analysis, and most have involved multiple drugs during perioperative procedures, limiting firm conclusions.  At 
the same time, OSA has become a major concern for anaesthesia care providers (Benumof, 2002; Chung et 
al., 2008).  Significant adverse respiratory outcomes have been reported in cases of obese patients with OSA 
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during perioperative management (Benumof, 2002; Agro et al., 2004). The American Society of 
Anesthesiologists has issued practice guidelines for the perioperative management of OSA patients to reduce 
the risk of adverse outcomes (Gross et al., 2006). However, relevant recommendations were primarily based 
on the consensus of consultants’ opinions (Gross et al., 2006; Chung et al., 2008). Similarly, sleep-disordered 
breathing was listed as a likely contributor to all opioid-related deaths mainly based on an expert panel’s 
opinion (Webster et al., 2011). In contrast, a few recent reviews and reports have questioned whether OSA is 
an independent risk factor for perioperative adverse events (Sabers et al., 2003; Ahmad et al., 2008; 
Ankichetty et al., 2011; Macintyre et al., 2011; Weingarten et al., 2011). These reviews suggest that these 
adverse events may be related to co-existing obesity (Weingarten et al., 2011).  Therefore clinical 
experimental trials are needed to investigate the effect of opioids on breathing during sleep including how 
these effects may relate to actual plasma drug levels. In the present study, we hypothesized that a commonly 
used single dose of oral morphine would impair awake ventilatory chemoreflexes and breathing during sleep in 
OSA patients and this would be related to plasma morphine levels.  
 
2. METHODS 
This experiment was conducted as a part of a proof-of-concept study examining the potential for the antibiotic 
minocycline to reverse opioid-induced respiratory depression. Data on minocyclcine are not reported. The 
study was conducted at the clinical sleep laboratory of Royal Prince Alfred Hospital (RPAH), a major teaching 
hospital of the University of Sydney. The study protocol was approved by Sydney South West Area Health 
Service (SSWAHS) Ethics Review Committee (Protocol No: X10-0268 & HREC/10/RPAH/476). Written 
consent forms were signed by all patients. The Australian & New Zealand Clinical Trial Registry number is 
ACTRN12610001074088. 
 
2.1. Patients and procedure 
Thirteen men with mild-moderate OSA were recruited from the sleep clinics of the Royal Prince Alfred Hospital 
and the associated Woolcock Institute of Medical Research from October 2010 to December 2010. Only men 
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were included due to potential ventilatory chemoreflex changes in women during the menstrual cycle (White et 
al., 1983). We excluded regular opiate users and those who had a history of adverse effects from opioids or 
minocycline, history of drug abuse, current CPAP users, current or recent severe physiological or 
psychological illness including severe cardiovascular (hypertension) or CNS diseases, and those with another 
severe sleep disorders, or concurrent use of other medications that might interfere with the study drugs.  
 
All patients underwent a baseline visit with overnight polysomnography (PSG) and awake ventilatory 
chemoreflex tests. Only those patients with apnea-hypopnea index (AHI) ≥ 10 and oxygen saturation (
2O
Sp ) 
nadir between 70-90% were included and asked to come back for the intervention study. 
 
In the intervention visit, patients finished dinner at 5 pm, and took a single oral dose of 30 mg slow-release 
morphine (MS Contin, Mundipharma Pty Limited, Sydney, Australia) at 5:30 pm. The drug will reach peak 
concentration at about 3 hours post-dose and have around a 12-hour duration of effect. Between 9 and 9:30 
pm, patients were tested for awake ventilatory chemoreflexes. Between 9:30 and 10 pm, 5 ml of venous blood 
was taken for drug concentration analyses. At 10 pm (lights off time), the PSG sleep study started and was 
recorded continuously until 7 am the next morning.   
 
2.2. PSG 
In-lab standard full PSGs (Alice 5, Philips Respironics, Andover, MA, USA) were monitored, including 4 
channels of electroencephalogram (EEG), 2 channels of electrooculogram (EOG), chin electromyelogram 
(EMG), anterior tibial EMG, electrocardiogram (ECG), body position, nasal pressure, chest and abdomen 
movements, and 
2O
Sp . PSG recordings were scored using Rechtschaffen and Kales criteria (Rechtschaffen 
and Kales, 1968), by an experienced sleep technologist who was blinded to treatment allocation. Respiratory 
events and arousals were scored according to standard Chicago and ASDA criteria respectively (American 
Sleep Disorders Association, 1992; AASM Task Force, 1999). AHI was calculated by dividing the total number 
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of apneas and hypopneas by the total sleep time (hours). Oxygen desaturation index (ODI) was calculated by 
dividing the total number of ≥3% 
2O
Sp dips by the total sleep time (hours).  
 
2.3. Ventilatory chemoreflex testing 
Central chemosensitivity, CO2 ventilatory recruitment threshold (VRT) and basal minute ventilation (VE) were 
measured using a fully computerised system using Duffin’s modified chemoreflex test (Duffin, 2010; Duffin, 
2011). An advantage of the Duffin’s modified rebreathing method is that VRT can be directly measured rather 
than being estimated using an extrapolated line. Central chemosensitivity was determined by testing the slope 
of iso-oxic hyper-oxic (holding oxygen constant at 150 mmHg) ventilatory response to CO2, as a 10-minute test 
while the patient was awake (Figure 1). The procedure included a 5-minute hyperventilation and a 5-minute of 
rebreathing through a closed circuit. During the hyperventilation, end-tidal 
2CO
P  was controlled between 19-25 
mmHg. The computer then switched the valve and the patient rebreathed for 5 minutes through a bag 
containing a mix gas of 6% of CO2 and 94% O2. The 
2O
P in the circuit was held constant at 150 mmHg. The 
computer continuously analysed O2 consumption over the past 3 breaths and used a prediction model to 
determine how much O2 to feed into the circuit. The VRT and central chemosensitivity (the slope of 
2CO
P  
plotted against minute ventilation) were analysed through purpose-built software. An example is shown in 
Figure 1.  
 
2.4. Drug analyses 
Plasma morphine concentrations were analysed at the laboratory of the Discipline of Pharmacology, The 
University of Adelaide. Plasma morphine concentrations were measured by LC/MS using a previously 
validated procedure (Somogyi et al., 2008). The intra- and inter-assay validation data showed accuracy > 90% 
and precision < 15% on quality control samples. The lower limits of quantification were 1 ng/ml. 
 
2.5. Statistical analysis 
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The main outcomes of interest were respiratory depression related parameters including overnight 
2O
Sp  nadir, 
percent of sleep time with 
2O
Sp < 90% (%T90), central chemosensitivity and VRT between baseline and 
morphine night. Descriptive data were expressed as mean ± SD, unless otherwise stated. Pair-wise 
comparisons were tested by paired t-test or Wilcoxon signed-rank test depending on normality of data 
distribution. Associations were tested by either Pearson’s or Spearman’s tests also based on normality of 
distribution. A p-value of less than 0.05 was considered as significant. Analyses were performed using SPSS 
(version 17; SPSS, Chicago, Illinois, USA).  
 
3. RESULTS 
Thirteen OSA patients were originally invited to participate. One declined due to a busy work schedule, and 
another due to concerns about potential side effects of morphine. Of the 11 patients randomised, one withdrew 
from the study due to severe nausea attributed to morphine. Ten patients completed the protocol. They had an 
average age of 47.6 ± 8.4 (range 37-65) years, BMI of 28.5 ± 3.2 (range 23.9-35.8) kg/m2. All the patients had 
baseline AHI between 10 and 30/hour. None of them were CPAP users. 
 
Two blood sample tubes were damaged during the interstate shipment, and hence were excluded from the 
blood related analysis. Average plasma morphine concentration is 7.25 ± 6.04 ng/ml. The patient who 
withdrew from the study with severe nausea had a blood morphine concentration of 2.25 ng/ml. 
 
The comparison of key ventilatory chemoreflex and PSG sleep and breathing parameters between the 
morphine arm and baseline is shown in Table 1. Compared to baseline, the administration of 30 mg slow 
release morphine did not cause statistically significant respiratory depression in any key PSG and ventilatory 
chemoreflex parameter. There was an average 33% reduction in central chemosensitivity in the “morphine 
plus placebo” night, but the difference did not reach statistical significance (p=0.18). There was a significant 
reduction in % rapid eye movement (REM) sleep (p<0.05) with morphine use, but the reduction did not cause 
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major change in REM related AHI or sleep time with 
2O
Sp <90% (T90) (Table 1). Average 
2O
Sp nadir during 
sleep paradoxically improved 4.4% with morphine use but did not reach significance (p=0.17). 
 
However, blood analyses showed that there was a large inter-individual difference (30 fold range) in morphine 
plasma concentration for the fixed dose of 30 mg oral controlled-release morphine (Figure 2). There was a 
significant positive correlation between a higher plasma morphine concentration in the morphine arm and the 
increase of the VRT from baseline (r=0.86, p=0.006) (Figure 2, Panel A). The higher plasma morphine 
concentration was also significantly associated with an improvement in the T90 from baseline (r=-0.87, p= 
0.005) (Figure 2, Panel B). In addition, the increase in VRT significantly correlated with reduction in T90 (r=-
0.79, p=0.02) (Figure 2, Panel C). Furthermore, we also found the higher plasma morphine concentration 
tended to correlate with an improvement in hypopnea index compared to the baseline (r=-0.66, p=0.07), but 
not with the change in apnea index (r=-0.30, p=0.46) (Figure 2, Panel D). No significant correlation was found 
between the change of central chemosensitivity and VRT or morphine concentration. 
 
4. DISCUSSION 
In contrast to our hypothesis, a commonly used single dose of oral morphine did not worsen breathing during 
sleep in this group of patients with mild-to-moderate sleep apnea. There was a strong correlation between   
higher plasma morphine concentrations and increased CO2 thresholds. However, paradoxically, this change in 
chemoreflex was linearly correlated with improvement in OSA. We propose that there is an intrinsic 
mechanistic link between the use of a mild dose of morphine, the decrease of ventilatory chemosensitivity, the 
increase of VRT/rhythm re-initiation threshold, the increase of CO2 reserve, and the improvement of mild-
moderate OSA (Figure 3). 
 
4.1. Inter-individual variability of morphine concentration 
In our study, for the fixed dose of 30 mg oral controlled-release morphine, there was a 30-fold range in plasma 
morphine concentrations. And the response variability is significantly associated with the large inter-individual 
9 
variability in plasma morphine concentration. Those showing no or little response had very low plasma 
morphine concentration (Figure 2). The large metabolism and respiratory variability may partly explain why 
opioids are a major cause of death by prescription medications, and why the opioid dose titration period is 
extremely dangerous (Caplehorn and Drummer, 1999; Ready, 2000; Centres for Disease Control and 
Prevention, 2007). Australian data showed that the relative risk (RR) of fatal accidental drug toxicity for 
patients in the first two weeks of methadone maintenance was 6.7 times that of heroin addicts not in the 
treatment program, and 97.8 times that of patients who had been on maintenance for more than two weeks 
(Caplehorn and Drummer, 1999). The variability may also explain why our pair-wise group comparisons were 
mostly not significant given a relevant small sample size, i.e. the group comparison did not take consideration 
of the large inter-individual difference in morphine plasma concentration. Our approach in this study is 
therefore mainly for concentration-effect, as a basic principle of clinical pharmacology.  
 
4.2. Morphine effect on VRT and central chemosensitivity 
For the first time, our study showed a strong correlation between a higher plasma morphine concentration and 
the increase of directly measured VRT. Elevated CO2 threshold by opioids have been inferred in previous 
human and animal studies using indirect estimate of 
2CO
P  threshold by extrapolating ventilatory response 
slope line (Berkenbosch et al., 1994; Lalley, 2004; Teppema et al., 2008). Morphine (Berkenbosch et al. 1994), 
M6G (Teppema et al., 2008) and fentanyl (Lalley, 2004) were found to increase estimated 
2CO
P  threshold in 
cats. The effect has also been reported in a human study through observing of a right shift of the steady-state 
CO2 response curve with morphine injection (Bourke and Warley, 1989). Importantly, increased CO2 
recruitment threshold usually related with decreased central chemosensitivity (Duffin, 2010). In the present 
study, mean central chemosensitivity reduced 33% with morphine across the patient group. Although, this 
effect was not statistically significant, the magnitude of the effect was comparable to previous work showing a 
42% reduction in ventilatory responses to hypercapnia before and after administration of 7.5 mg of morphine 
sulphate subcutaneously in six normal subjects (Weil et al., 1975). Data in cats have also shown a similar 30% 
reduction in CO2 sensitivity following intravenous 0.15 mg/kg morphine (Berkenbosch et al., 1997). An obvious 
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question is why we did not find similar concentration effect in central chemosensitivity. A likely explanation is 
that measurement variability for central chemosensitivity is much higher than VRT. A recent study investigated 
variability of Duffin method and found that VRT has a minimal between day measurement variability 
(coefficient of variation ≈ 3), while the variability for central chemosensitivity is around 10 fold higher (Jensen 
et al., 2010).  This would suggest that for a small sample size, it could be much easier to find a physiological 
response correlated with VRT, while group comparison is more suitable for chemosensitivity. In summary, our 
data may generally suggest a combination effect of increased VRT and reduced central chemosensitivity with 
morphine use.  
 
4.3. Morphine effect on breathing stability during sleep 
A surprising finding from our study is that, for the first time, we demonstrated a paradoxical improvement in 
oxygenation during sleep in patients with OSA with higher plasma morphine concentrations (Figure 2, Panel B), 
and moreover, the improvement of the oxygenation in OSA was linked to a higher VRT (Panel C). These 
findings may be counter-intuitive when considering the effects of narcotic overdose on breathing but in this 
study of a standard single dose of oral morphine are congruent with recent advances in the understanding of 
respiratory control during wake and sleep in patients with OSA (Dempsey, 2004; Dempsey et al., 2004; White, 
2005; Younes, 2008; Edwards et al., 2012). 
 
Our VRT was measured by beginning with 5 minutes of hyperventilation with end-tidal 
2CO
P  between 19-
25mmHg, levels lower than the VRT. Following this, rebreathing is initiated to allow 
2CO
P  to increase, but 
ventilation does not increase until 
2CO
P  crosses the VRT, where we observed ventilation linearly increasing in 
response to hypercapnia. This is demonstrated in Figure 1. This mechanism is analogous with the breathing 
seen in OSA, with apnea occurring after a period of ventilatory overshoot, there are still respiratory tone but 
ventilation does not increase until 
2CO
P  crosses the rhythm reinitiation threshold (RRT) (Dempsey, 2004). 
From the above mechanisms, we believe that it is reasonable to estimate that VRT during awake is parallel to 
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RRT during sleep, and could be around 3 mmHg higher due to the wakefulness drive.  Similarly, it is 
reasonable to believe that a high central chemosensitivity (the slope response in Figure 2) measured during 
awake represent a high chemical drive during sleep (Mateika et al., 2004; Beecroft et al., 2006).  
 
During sleep, CO2 reserve, which is the difference in 
2CO
P between apnea initiation threshold (AIT) and RRT, 
is a key determinant of breathing instability (Dempsey, 2004; Dempsey et al., 2004) (Figure 3). A narrower 
CO2 reserve indicates a greater breathing instability, and a widened CO2 reserve leads to a greater breathing 
stability (Dempsey, 2004; Dempsey et al., 2004). Typical examples are “Cheyne-Stokes” respiration in 
congestive heart failure patients and the effect of hypoxia in high altitude, where CO2 reserve become much 
narrower with frequent disordered-breathing events. CO2 reserve is highly labile and varies inversely with the 
slope of ventilatory response below eupnea (Dempsey et al., 2004). OSA has been characterized with high 
loop gain/chemical drive/chemosensitivity which can cause ventilatory over-shoot, and the repetitive pattern is 
crucial in precipitating a cyclic sleep-disordered breathing pattern (White, 2005; Dempsey et al., 2010). In our 
OSA patients, the mild dose of morphine may reduce ventilatory chemosensitivity, and therefore the controller 
gain and the chance of cyclic ventilatory overshoot,  thus improve OSA (Edwards et al., 2012; Wang et al., 
2011). On the other hand, the increased VRT in our OSA patients may indicate an increased RRT and a 
widened CO2 reserve, and a greater breathing stability during sleep. As shown in Figure 3, we suspect the two 
factors act together and play the key role for the underlying mechanism. The improved oxygenation with higher 
concentrations of morphine, in our sample of OSA patients and the trend of significant correlation between 
plasma morphine concentration and the change of the hypopnea index support this potential mechanism 
(Figure 2, Panel D).  The positive effect on OSA was not reflected in studying the group as a whole, probably 
as a consequence of the individual variability in morphine concentrations (Table 1, Figure 2). Nevertheless, 
although no significant differences were demonstrated, the mean 
2O
Sp  nadir in these 10 OSA patients 
increased from 79.1% in baseline to 83.5% in the morphine arm, and the T90 decreased from 2.81 to 1.83 
mins (Table 1).  
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4.4. Clinical implications 
It will be important in the future to examine the effects of higher doses of morphine, but it is unlikely the lower 
doses that were used in this study have a negative impact on patients with mild-moderate sleep apnea. The 
American Society of Anesthesiologists has issued practice guidelines for the perioperative management of 
OSA patients to reduce the risk of adverse outcomes (Gross et al., 2006). However, relevant 
recommendations were primarily based on the consensus of consultants’ opinions (Gross et al., 2006; Chung 
et al., 2008). No properly designed prospective clinical study has investigated the effect of opioids on OSA 
(Chung et al., 2008; Macintyre et al., 2011). Interestingly, a retrospective study compared 234 OSA patients 
with matched controls did not find OSA is a risk factor for adverse events among patients undergoing 
outpatient surgical procedures (Sabers et al., 2003). Evidence supporting an increased risk of perioperative 
complications in OSA patients often reported in patients who also have significant obesity (Macintyre et al., 
2011). A large retrospective review of 797 patients found that obesity rather than OSA severity is associated 
with postoperative and overall complication rates (Weingarten et al., 2011). Our patients mostly had moderate 
OSA. Patients with more obesity, more severe OSA and a highly collapsible airway may possibly worsen their 
sleep disordered breathing with even modest doses of opioid. Opioids do suppress upper airway muscle 
activity in animals (Hajiha et al., 2009). A specifically designed study with a larger sample size and 
measurements of upper airway collapsibility, over-night loop gain/chemoreflex testing is needed to better 
investigate the effects of opioids on a wider range of patients with OSA.   
 
We speculate that our findings may suggest an additional direction in pharmacological treatment of sleep 
apnea in certain patients. We (Wang et al., 2011) and others (Eckert et al., 2011; Edwards et al., 2012) have 
identified certain respiratory phenotypes that may characterise sub-groups of OSA patients that will improve 
sleep apnea following use of CNS depressants. In these patients, the use of safe doses of a respiratory 




It is important to recognise that our findings are preliminary based on a proof-of-concept study limited by a low 
dose of opioid and less severe OSA patients. These choices of patients and opioid dosage were required by 
safety and ethical considerations. We would expect to see a higher dose of morphine cause more significant 
respiratory depression. With the large inter-individual variability in opioid concentrations, this factor may well 
be crucial in determining which patients develop respiratory depression or respiratory arrest following opioid 
administration. Ideally, future studies can adopt double-blind, placebo-controlled design with an extra arm 
testing over-night ventilatory chemoreflexes using mechanical ventilation techniques. It could provide direct 
evidence for our proposed mechanism by comparing the measurements of sleep parameters like ventilatory 
response to CO2 above and below eupnea, RRT, AIT and CO2 reserve, with awake chemoreflex parameters.  
Furthermore, we could ideally include peripheral chemoreflex test as part of the awake chemoreflex test which 
could better explain the potential mechanisms (Wang et al., 2011). We did not test this as we have very limited 
window of time after the slow-release morphine taking effect (9 pm) and before sleep time (10 pm). For the 
same reason, we could not repeatedly test the chemoreflexes to assess potential variability of the tests.  
 
5. CONCLUSIONS 
In mild-to-moderate OSA patients, a single common dose of oral morphine may paradoxically improve OSA 
through modulating chemoreflexes. There is a large inter-individual variability in the responses which may 
relate to individual morphine metabolism. These data question the assumption that small doses of opioids are 
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Figure 1. An example of the ventilatory chemoreflex analyses from our data. “Slope” is the central 
chemosensitivity. “VRT” is the CO2 ventilatory recruitment threshold. 
 
Figure 2. Between the morphine arm and baseline, significant associations were found between individual 
plasma morphine concentration and the change of awake VRT (Panel A), and the change of Sleep Time with 
2O
Sp  <90% (T90) (Panel B). Panel C shows the association between the change of VRT and the change of 
T90 min. Panel D shows that a higher plasma morphine concentration tended to correlate with an 
improvement in hypopnoea index compared to the baseline. The changes were calculated by (morphine arm – 
baseline).  
 
Figure 3. Potential mechanism of acute morphine effect on breathing instability in OSA. We would like to 
emphasize that the effect we refer to is that of a mild dose of acute morphine on mild-to-moderate OSA. To 
make it easier to compare between the CO2 reserves, we present each condition as starting from the same 
“apnea initiation threshold” (AIT). 
 













































VE= minute ventilation; VRT= CO2 ventilatory recruitment threshold; TST=total sleep time; SE=Sleep Efficiency; 
REM= Rapid eye movement sleep; SWS=Slow wave sleep; ArI= Arousal Index; CSA (min) = total minutes of 
central sleep apnea events; OSA (min) = total minutes of OSA events; Hypopnea (min) = total minutes of 
hypopnea events; CAI= Central apnea index; ODI= Oxygen desaturation index; AHI= Apnea hypopnea index; 
NREM= Non-REM sleep; 
2O
Sp  low= 
2O




Table 1. Comparison of ventilatory chemoreflex and PSG parameters in the morphine arm and in baseline.  
 
 
 Morphine Baseline p 
VE-basal (l/min) 12.06±4.26 12.59 ±5.29 0.721 
VRT (mmHg) 46.99 ±2.48 47.02±4.59 0.98 
Central Chemosensitivity 
(l/min/mmHg) 1.45±0.75 2.16 ±1.26 0.185 
TST (min) 371.20 ±56.96 351.67±56.93  0.066 
SE (%) 80.67±10.62  80.00±9.37  0.801 
REM (%) 10.78±3.76   15.95±6.47  0.042 
SWS (%) 16.83±10.36 20.66±6.33  0.323 
ArI (/hr) 17.80±7.67   21.82±9.92  0.256 
CSA (min) 1.87±3.61  0.51±1.18  0.254 
OSA (min) 13.51±16.77 10.59±8.34  0.578 
Hypopnea (min) 37.73±25.48  40.68±27.14 0.535 
CAI (/hr) 0.99±1.80  0.29±0.64  0.248 
Hypopnea Ratio (%) 0.78±0.16  0.77±0.20   0.828 
ODI (/hr) 12.06±12.06 10.15±6.35 0.878 
AHI (/hr) 22.15±17.08  19.54±6.91 0.799 
AHI-REM (/hr) 28.46±21.90 33.06±18.19 0.514 
AHI-NREM (/hr) 21.18±17.71 17.33±9.46 0.424 
2O
Sp  low (%) 83.50±7.34 79.10 ±7.74 0.173 
%T90  1.83±2.08 2.81±3.72 0.551 
T90-REM (min) 1.37±1.78 1.969±2.58 0.438 
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